
Sign up to save your podcasts
Or
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week’s podcast.
4.9
837837 ratings
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week’s podcast.
134 Listeners
13 Listeners
313 Listeners
173 Listeners
494 Listeners
18 Listeners
278 Listeners
3,324 Listeners
90 Listeners
137 Listeners
1,113 Listeners
58 Listeners
193 Listeners
514 Listeners
349 Listeners
60 Listeners
25 Listeners
8 Listeners
426 Listeners
364 Listeners